肺癌中的CXCR4向治疗:plerixafor作为一个有前途的抗转移药物
Prasanna Srinivasan Ramalingam1, Muhammad Afzal2, M Arockia Babu3
1Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Frontiers in pharmacology
|December 12, 2025
概括
用plerixafor准CXCR4在肺癌中表现有前途,因为它可以限制转移并提高治疗效率. 需要进一步的研究来克服挑战,并优化组合疗法,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
背景情况:
- 转移是肺癌预后不良的主要驱动因素.
- CXCR4/CXCL12轴对肺癌的进展,免疫逃避和治疗耐药性至关重要.
- 在非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 中高CXCR4表达与侵袭性疾病和低生存率相关.
研究的目的:
- 审查CXCR4在肺癌发病过程中的作用.
- 总结一下最近关于plerixafor抑制CXCR4的发现.
- 探索针对CXCR4的新型组合治疗策略.
主要方法:
- 对plerixafor作为CXCR4抑制剂的临床前研究的审查.
- 对结合plerixafor与化疗和免疫检查点抑制剂在NSCLC的临床试验数据的分析.
- 探索CXCR4向疗法的药物开发策略.
主要成果:
- 在临床前模型中,plerixafor减少了瘤细胞迁移,增强了化学敏感性,并恢复了免疫反应.
- 临床试验显示plerixafor增加T细胞透,抗瘤免疫力和无进展存活期在NSCLC患者.
- 通过CXCR4成像和生物标志物选择,可以改善精准医学方法.
结论:
- 用plerixafor针对CXCR4提供了一个有前途的肺癌治疗策略.
- 针对瘤异质性,耐药性机制和瘤微环境是CXCR4向治疗的关键.
- 结合疗法,包括化学疗法,放射疗法和免疫疗法,以及精密医学,是最大限度地获得益处的关键.
关键词:
CXCR4CXCR4CXCR4CXCR4CXCR4CXCR4CXCR4CXCR4CXCR4CXCR4C免疫细胞迁移的迁移肺癌是一种肺癌.转移 转移 转移 转移在plerixafor上使用.预后 预后 预后瘤微环境 (TME) 是指瘤的微环境.瘤进展的进展情况更多相关视频
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
1.7K
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
9.4K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K